Log In
BCIQ
Print this Print this
 

MK-8892

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionSoluble guanylate cyclase (sGC) modulator
Molecular Target Soluble guanylate cyclase (sGC)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationHypertension
Indication DetailsTreat pulmonary arterial hypertension
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2,100.0M

$1,000.0M

$1,100.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/12/2014

$2,100.0M

$1,000.0M

$1,100.0M

Get a free BioCentury trial today